Parminder Singh, MD, presented “FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial Cancer” at the 6th International Bladder Cancer Update on November 20, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Singh, Parminder “FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial Cancer.” November 2022. Accessed Aug 2024. https://grandroundsinurology.com/fgfr-kinase-inhibitors-and-other-novel-targets-in-the-treatment-of-metastatic-urothelial-cancer/
FGFR Kinase Inhibitors and Other Novel Targets in the Treatment of Metastatic Urothelial Cancer – Summary
Parminder Singh, MD delves into the evolving landscape of treatments for metastatic urothelial cancer, with a particular focus on FGFR kinase inhibitors and other novel therapeutic targets. Dr. Singh provides a comprehensive overview of the genetic and molecular underpinnings of urothelial cancer, emphasizing the significant role of FGFR (fibroblast growth factor receptor) alterations in the disease’s progression and treatment resistance.
He highlights the latest advancements in FGFR kinase inhibitors, detailing their mechanisms of action, efficacy, and safety profiles. Dr. Singh underscores the clinical benefits observed in patients with FGFR-altered urothelial cancer, citing recent clinical trials and real-world studies that demonstrate improved outcomes and manageable side effects. These inhibitors, he notes, represent a promising addition to the therapeutic arsenal against metastatic urothelial cancer, particularly for patients who have exhausted conventional treatment options.
In addition to FGFR kinase inhibitors, Dr. Singh explores other emerging targets and therapies in urothelial cancer treatment. He discusses the potential of novel agents that inhibit other critical pathways and proteins involved in cancer cell proliferation and survival. The lecture covers the latest research findings on these innovative therapies, providing insights into their clinical development stages and potential future applications.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Dr. Parminder Singh, MD, is an Assistant Professor of Hematology and Oncology at Mayo Clinic in Phoenix, Arizona, and a Genitourinary oncologist who specializes in bladder cancer with research focus in developing novel therapeutics. He is the Study Chair on SWOG 1806, which is a phase III clinical trial evaluating trimodality therapy in combination with atezolizumab in muscle-invasive bladder cancer.
